Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEε4 carriers in the Australian population

Abstract

Apolipoprotein E-ε4 (APOEε4) has been associated with increased risk of developing Alzheimer's disease (AD) and regional cerebral glucose hypometabolism, as measured by fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). We report here preliminary data from studies that aim to determine whether cerebral glucose hypometabolism is observed in APOEε4 positive, cognitively intact individuals between the ages of 50 and 80, and whether there is an additional impact of subjective memory complainer (SMC) status on glucose metabolism determined by NeuroStat analysis. FDG-PET was conducted in 30 community dwelling, APOE-ε4 carriers without clinical evidence of dementia and objective cogni..